More than 46 million turkeys will be cooked this Thanksgiving holiday, according to the National Turkey Federation. In an effort to help protect Americans from foodborne illness during the Thanksgiving season, the Ad Council, the U.S. Department of Agriculture (USDA)’s Food Safety and Inspection Service, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), in partnership with Food Network Star’s Martie Duncan, are helping to dispel many of the common myths surrounding the preparation and serving of the holiday turkey meal.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59193-ad-council-usda-hhs-food-safe-families-public-service-thanksgiving
Dune Medical Devices, Inc., announced today that its breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, the MarginProbe System, has received Premarket Approval (PMA) by the United States Food and Drug Administration. The technology significantly improves surgeons’ ability to intra-operatively identify
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
Diabetes experts met and determined that some self-monitoring blood glucose (SMBG) systems, despite meeting accuracy standards at the time of U.S. Food and Drug Administration (FDA) clearance, fail to consistently meet accuracy standards once on the market, potentially putting patient health at risk. In a public meeting convened by the Diabetes Technology Society on May 21, 2013, in Arlington, Virginia, leading academic clinicians, clinical chemists, medical device experts, patient advocates and FDA representatives reviewed a growing body of peer-reviewed research demonstrating that the performance of some blood glucose monitors on the market may not be meeting accuracy standards.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/61870-diabetes-technology-society-inaccurate-blood-glucose-monitors-risky
With their high quality protein and other essential nutrients, fish and shellfish are important parts of a healthful diet. But, as with any food, safe handling is essential to reducing the risk of foodborne illness, often called “food poisoning.” Follow these basic food safety tips for buying, storing, and preparing fish and shellfish.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/54147-u-s-fda-safe-food-handling-tips-fish-shellfish-reduce-risk-food-poisoning
Teaming up with the American Diabetes Association® and the multi-talented performer and caretaker Joey Fatone @RealJoeyFatone, Colgate Total® is using the power of laughter to help raise awareness of the potential link between oral health and diabetes with the new “30 Days of Laughter” campaign (#30DaysofLOL), beginning today. The 30 days from November 12 to December 11, 2015 will be filled with laugh-out-loud videos, funny social media posts, engaging apps and more to make the diabetes community laugh, all while building awareness of the importance of maintaining the health of the teeth and gums behinds those smiles.
According to the Centers for Disease Control and Prevention, people with diabetes are two times more likely to develop gum disease1. Colgate Total® toothpaste can help prevent and even reverse gingivitis, the most common form of gum disease. It is the only FDA-approved and American Dental Association-accepted2 toothpaste to help prevent gingivitis. With regular twice daily brushing, you can help improve your gum health in as little as four weeks3 with Colgate Total®.
Understanding how challenging managing diabetes can sometimes be, the funny and talented performer Joey Fatone is leading the “30 Days of Laughter” campaign to remind people that sometimes laughter can feel like the best medicine. “When my father was diagnosed with Type 2 diabetes, our family was shocked. But we’re a big, loving group and we all help him together every day. I know that humor in the face of challenges is vital and I’m excited to share that with other families touched by diabetes.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7654951-colgate-30-days-of-laughter/
For the millions who suffer from Gastroesophageal Reflux Disease (GERD), a study published today in the New England Journal of Medicine (NEJM) provides clinical evidence of safety and effectiveness for a new, FDA-approved medical device. Torax Medical’s LINX® Reflux Management System was studied in a controlled, prospective, multicenter trial involving 14 U.S. and European medical centers as part of the FDA pre-market approval process. The patients were evaluated before and after treatment to determine the effect of the LINX System on their GERD using pre-defined success criteria, which included reduction of esophageal acid, improvement in quality of life and elimination of reflux medications.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60077-torax-medical-linx-reflux-management-system-clinical-study-published
Since ancient times, the egg has been regarded as a symbol of new life and has been associated with springtime celebrations, such as Easter and Passover. But, even during festive occasions, eggs can cause food poisoning (also called foodborne illness) if they are not handled properly. That’s why the U.S. Food and Drug Administration (FDA) reminds consumers to handle fresh eggs safely during their springtime celebrations and throughout the year.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7231951-u-s-fda-egg-safety/
Hologic, Inc. (NASDAQ: HOLX) is kicking off Breast Cancer Awareness Month with the announcement that the Company's groundbreaking 3D mammography exam, available on the Selenia Dimensions platform, will be introduced to consumers today as Genius 3D Mammography. Hologic’s Genius 3D Mammography is the only 3D exam approved by the FDA as clinically superior to traditional mammography.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7254155-hologic-new-consumer-awareness-campaign-mammography-technology/
Nearly 12 million men in the U.S. suffer from symptoms related to benign prostatic hyperplasia (BPH), an enlargement of the prostate that can cause issues such as frequent and weak urinary streams and sleep deprivation from getting up repeatedly during the night to urinate. Since traditional BPH therapies such as daily medications and more invasive or surgical procedures often result in unwanted side effects and complications, more than 54 percent of men who would benefit from treating their BPH choose not to do anything1. With today’s national introduction of the FDA-cleared Rezūm® System, NxThera provides urologists and their patients suffering from symptomatic BPH with a new, safe and effective minimally-invasive, office-based treatment option which improves quality of life and preserves sexual function2 – one of the main reasons many men choose to forego medications or more invasive procedures.
“Men suffering from BPH are constantly evaluating the trade-offs between maintaining their current declined quality of life or treating their BPH symptoms and possibly incurring long term side effects,” said Dr. Kia Michel, M.D., a urologist at Comprehensive Urology in Los Angeles who recently performed the procedure as part of a nationally televised segment on prostate health. “Of all the minimally-invasive BPH treatments I’ve performed, Rezūm is the most effective and most versatile treatment available to patients – and the results have been excellent.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7933151-nxthera-rezum-therapy/
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
